



162
Dkt. 56613-A/JPW/AJM/AAB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed : February 20, 2004
For : Method for Determining Whether a Compound
is Capable of Inhibiting the Interaction
of a Peptide with RAGE

1185 Avenue of the Americas
New York, New York 10036
October 14, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (Exhibit A).

1. U.S. Patent No. 5,864,018, filing date April 16, 1996 (Morser et al.).
2. Morser, et al., PCT International Application No. PCT/EP97/01832, filed 11 April 1997, published October 23, 1997, Publication No. WO 97/39121, Advanced Glycation Endproduct Receptor Peptides and Uses Thereof.
3. Morser, et al., PCT International Application No. PCT/EP97/01834, filed April 11, 1997, published October

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/783,635
Filed : February 20, 2004
Page 2

23, 1997; Publication No. WO 97/39125, Antibodies Against the Advanced Glycation Endproduct Receptor and Uses Thereof.

4. Stern, et al., PCT International Publication No. WO 97/26913, The Trustees of Columbia University in the City of New York. A polypeptide from lung extract which binds amyloid- β peptide, PCT International Application No. PCT/US97/00857 (published July 31, 1997).
5. International Search Report issued for International Application No. PCT/US99/23245, filed October 5, 1999.
6. Brett, J., et al. (1993) Survey of the distribution of a newly-characterized receptor for AGEs in tissues. *Am. J. Pathol*, 143:1699-1712.
7. Bucala, et al. (1994) Modification of Low Density Lipoprotein by Advanced Glycation End Products Contributes to the Dyslipidemia of Diabetes and Renal Insufficiency, *PNAS, USA* 91:9441-9445.
8. Fu, M. X., et al. (1996) The Advanced Glycation Endproduct, N^e-(Carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions. *J. Biol. Chem.*, 271:9982-9986.
9. Khoury, J., et al. (1994) Macrophages adhere to glucose-modified basement membrane via their scavenger receptors. *J. Biol. Chem.*, 269:10197-10200.

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/783,635
Filed : February 20, 2004
Page 3

10. Lander, H. L., et al. (1997) Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress. *J. Biol. Chem.*, 272:17810-17814.
11. Li, J., et al. (1997) Characterization and functional analysis of the promoter of RAGE, the Receptor for Advanced Glycation Endproducts. *J. Biol. Chem.*, 272:16498-16506.
12. Mackic, et al. (Aug. 1998) Human Blood-brain barrier for Alzheimer's Amyloid-beta 1-40. *J. Clin. Invest.* 102(4):734-743.
13. Marui, N., et al. (1993) VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells. *J. Clin. Invest.*, 92:1866-1874.
14. Miyata, T., et al. (1996) The Receptor for Advanced Glycation Endproducts (RAGE) mediates the interaction of AGE-b₂-Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. *J. Clin. Invest.* 98:1088-1094.
15. Park, L., et al. (1998) Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). *Nature Medicine*, 4:1025-1031.
16. Portero-Otin, M., et al. (1995) Chromatographic evidence

for pyrraline formation during protein glycation *in vitro* and *in vivo*. *Biochim. Biophys. Acta*, 1247:74-80.

17. Reddy, S., et al. (1995) N^ε-(Carboxymethyl)lysine is a dominant Advanced Glycation Endproduct (AGE) antigen in tissue proteins. *Biochemistry*, 34:10872-10878.
18. Schleicher, E. D., et al. (1997) Increased accumulation of the glycoxidation product N^ε-(Carboxymethyl)lysine in human tissues in diabetes and aging. *J. Clin. Invest.*, 99:457-468.
19. Schmidt, A. M., et al. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. *J. Clin. Invest.* 92:2155-2168.
20. Schmidt, A. M., et al. (1997) The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes. *Circulation Supplement*, 96:#194, p. I -37.
21. Schmidt, A. M., et al. (1994) The endothelial cell binding site for advanced glycation endproducts consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. *J. Biol. Chem.*, 269:9882-9888.
22. Schmidt, A. M., et al. (1992) Isolation and characterization of binding proteins for advanced glycation endproducts from lung tissue which are present

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/783,635
Filed : February 20, 2004
Page 5

on the endothelial cell surface. *J. Biol. Chem.*,
267:14987-14997.

23. Schmidt, A. M., et al. (1994) Cellular receptors for advanced glycation end products. *Arterioscler. Thromb.*, 14:1521-1528.
24. Schmidt, A. M., et al (1995) The Dark Side of Glucose (News and Views). *Nature Medicine*, 1:1002-1004.
25. Schmidt, A. M., et al. (1994) Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. *Proc. Natl. Acad. Sci. (USA)*, 91:8807-8811.
26. Schmidt, A. M., et al. (1995) AGE interaction with their endothelial receptor induce expression of VCAM-1: a potential mechanism for the accelerated vasculopathy of diabetes. *J. Clin. Invest.*, 96:1395-1403.
27. Schreiber, E., et al. (1989) Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. *Nucleic Acids Research*, 17:6419.
28. Sell, D. R., et al. (1989) Structure elucidation of a senescence cross-link from human extracellular matrix. *J. Biol. Chem.*, 264:21597-21602.
29. Shamsi, F. A., et al. (1998) Immunological evidence for methylglyoxal-derived modifications *in vivo*. *J. Biol.*

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/783,635
Filed : February 20, 2004
Page 6

Chem., 273:6928-6936.

30. Soulis, T., et al. (1997) Advanced glycation endproducts and their receptors co-localize in rat organs susceptible to diabetic microvascular injury. *Diabetologia*, 40:619-628.
31. Vlassara, H., et al. (1995) Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex. *Molecular Medicine*, 1:634-646.
32. Wautier, J. L., et al. (1996) Receptor-mediated endothelial dysfunction in diabetic vasculopathy: sRAGE blocks hyperpermeability in diabetic rats. *J. Clin. Invest.*, 97 (1):238-243.
33. Wu, J., et al. (1997) The soluble receptor for Advanced Glycation Endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. *Plastic Surgery Research Council*, Abstract 77:43.
34. Yan, S. D., et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. *J. Biol. Chem.*, 269:9889-9897.
35. Yang, Z., et al (1991) Two novel rat liver membrane proteins that bind AGEs: relation to macrophage receptor for glucose-modified proteins. *J. Exp. Med.*, 174:515-524.

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/783,635
Filed : February 20, 2004
Page 7

The subject application is a continuation of and claims the benefit under 35 U.S.C. §120 of U.S. Serial No. 09/166,649, filed October 5, 1998, now U.S. Patent No. 6,753,150 B2, issued June 22, 2004.

Above-listed references 6, 8-11 and 13-35 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed on April 15, 1999 in connection with U.S. Serial No. 09/166,649, filed October 5, 1998, now U.S. Patent No. 6,753,150 B2, issued June 22, 2004. Above-listed references 2, 3, 5, 7 and 12 were submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on April 10, 2000 in connection with U.S. Serial No. 09/166,649, filed October 5, 1998, now U.S. Patent No. 6,753,150 B2, issued June 22, 2004. Above-listed references 1 and 4 were cited by the United States Patent and Trademark Office in an Office Action dated July 10, 2000 in connection with U.S. 09/166,649, filed October 5, 1998, now U.S. Patent No. 6,753,150 B2, issued June 22, 2004. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier effective filing date under 35 U.S.C. §120.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/783,635
Filed : February 20, 2004
Page 8

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alan J. Morrison
Reg. No. 37,399

Date

10/14/04

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400



Form PTO-1449

U.S. Department of
Commerce

Patent and Trademark Office

Atty. Docket No.
575-56613-A/
JPW/AJM/AABSerial No.
10/783,635Applicant(s)
Ann Marie Schmidt, et al.Filing Date
February 20, 2004

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5 8 6 4 0 1 8	1/26/99	Morser, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	9 7 3 9 1 2 1	10/23/97	PCT				
	WO	9 7 3 9 1 2 5	10/23/97	PCT				
	WO	9 7 2 6 9 1 3	07/31/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	International Search Report issued for International Application No. PCT/US99/23245, filed October 5, 1999;
	Brett, J, et al. (1993) Survey of the distribution of a newly-characterized receptor for AGEs in tissues. <i>Am. J. Pathol.</i> , 143:1699-1712;
	Bucala et al. (1994) Modification of Low Density Lipoprotein by Advanced Glycation End Products Contributes to the Dyslipidemia of Diabetes and Renal Insufficiency, <i>PNAS</i> , USA 91:9441-9445;
	Fu, M. X., et al. (1996) The Advanced Glycation Endproduct, N ^e -(Carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions. <i>J. Biol. Chem.</i> , 271:9982-9986;
	Khoury, J., et al. (1994) Macrophages adhere to glucose-modified basement membrane via their scavenger receptors. <i>J. Biol. Chem.</i> , 269:10197-10200;

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-56613-A/
JPW/AJM/AABSerial No.
10/783,635INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
February 20, 2004

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lander, H. L., et al. (1997) Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress. <i>J. Biol. Chem.</i> , 272:17810-17814;
	Li, J. and Schmidt, A. M. (1997) Characterization and functional analysis of the promoter of RAGE, the Receptor for Advanced Glycation Endproducts. <i>J. Biol. Chem.</i> , 272:16498-16506;
	Mackic, et al. (Aug. 1998) Human Blood-brain barrier for Alzheimer's Amyloid-beta 1-40. <i>J. Clin. Invest.</i> 102(4):734-743;
	Marui, N., et al. (1993) VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells. <i>J. Clin. Invest.</i> , 92:1866-1874;
	Miyata, T., et al. (1996) The Receptor for Advanced Glycation Endproducts (RAGE) mediates the interaction of AGE-b ₂ -Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. <i>J. Clin. Invest.</i> 98:1088-1094;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 575-56613-A/ JPW/AJM/AAB		Serial No. 10/783,635	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicant(s) Ann Marie Schmidt, et al.			
		Filing Date February 20, 2004		Group Art Unit	

U.S. PATENT DOCUMENTS									
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		

FOREIGN PATENT DOCUMENTS									
Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation		
							Yes	No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Park, L., et al. (1998) Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). <i>Nature Medicine</i> , 4:1025-1031;		
	Portero-Otin, M., et al. (1995) Chromatographic evidence for pyrraline formation during protein glycation <i>in vitro</i> and <i>in vivo</i> . <i>Biochim. Biophys. Acta</i> , 1247:74-80;		
	Reddy, S., et al. (1995) N ^e -(Carboxymethyl)lysine is a dominant Advanced Glycation Endproduct (AGE) antigen in tissue proteins. <i>Biochemistry</i> , 34:10872-10878;		
	Schleicher, E. D., et al. (1997) Increased accumulation of the glycoxidation product N ^e -(Carboxymethyl)lysine in human tissues in diabetes and aging. <i>J. Clin. Invest.</i> , 99:457-468;		
	Schmidt, A. M., et al. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. <i>J. Clin. Invest.</i> 92:2155-2168;		
<table style="width: 100%;"> <tr> <td style="width: 40%;">EXAMINER</td> <td>DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-56613-A/
JPW/AJM/AABSerial No.
10/783,635Applicant(s)
Ann Marie Schmidt, et al.Filing Date
February 20, 2004

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Schmidt, A. M., et al. (1997) The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes. <i>Circulation Supplement</i> , 96:#194, p. I -37;
	Schmidt, A. M., et al. (1994) The endothelial cell binding site for advanced glycation endproducts consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. <i>J. Biol. Chem.</i> , 269:9882-9888;
	Schmidt, A. M., et al. (1992) Isolation and characterization of binding proteins for advanced glycation endproducts from lung tissue which are present on the endothelial cell surface. <i>J. Biol. Chem.</i> , 267:14987-14997;
	Schmidt, A. M., et al. (1994) Cellular receptors for advanced glycation end products. <i>Arterioscler. Thromb.</i> , 14:1521-1528;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-56613-A/
JPW/AJM/AABSerial No.
10/783,635INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
February 20, 2004

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Schmidt, A. M., et al (1995) The Dark Side of Glucose (News and Views). <i>Nature Medicine</i> , 1:1002-1004;
	Schmidt, A. M., et al. (1994) Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. <i>Proc. Natl. Acad. Sci. (USA)</i> , 91:8807-8811;
	Schmidt, A. M., et al. (1995) AGE interaction with their endothelial receptor induce expression of VCAM-1: a potential mechanism for the accelerated vasculopathy of diabetes. <i>J. Clin. Invest.</i> , 96:1395-1403;
	Schreiber, E., et al. (1989) Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. <i>Nucleic Acids Research</i> , 17:6419;
	Sell, D. R., et al. (1989) Structure elucidation of a senescence cross-link from human extracellular matrix. <i>J. Biol. Chem.</i> , 264:21597-21602;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-56613-A/
JPW/AJM/AABSerial No.
10/783,635**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
February 20, 2004

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Shamsi, F. A., et al. (1998) Immunological evidence for methylglyoxal-derived modifications <i>in vivo</i> . <i>J. Biol. Chem.</i> , 273:6928-6936;
	Soulis, T., et al. (1997) Advanced glycation endproducts and their receptors co-localize in rat organs susceptible to diabetic microvascular injury. <i>Diabetologia</i> , 40:619-628;
	Vlassara, H., et al. (1995) Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex. <i>Molecular Medicine</i> , 1:634-646;
	Wautier, J. L., et al. (1996) Receptor-mediated endothelial dysfunction in diabetic vasculopathy: sRAGE blocks hyperpermeability in diabetic rats. <i>J. Clin. Invest.</i> , 97 (1):238-243;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Atty. Docket No. 575-56613-A/ JPW/AJM/AAB	Serial No. 10/783,635
	Applicant(s) Ann Marie Schmidt, et al.	
	Filing Date February 20, 2004	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Wu, J., et al. (1997) The soluble receptor for Advanced Glycation Endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. <i>Plastic Surgery Research Council</i> , Abstract 77:43;
	Yan, S. D., et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. <i>J. Biol. Chem.</i> , 269:9889-9897;
	Yang, Z., et al (1991) Two novel rat liver membrane proteins that bind AGEs: relation to macrophage receptor for glucose-modified proteins. <i>J. Exp. Med.</i> , 174:515-524.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.